New scan could predict if radioactive iodine will work for thyroid cancer

NCT ID NCT03647358

Recruiting now Diagnosis Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new PET scan using a special form of iodine called iodine-124 to measure how much radioactive iodine thyroid cancer tumors absorb. The goal is to help doctors decide if standard radioactive iodine therapy is likely to help. About 60 adults with metastatic thyroid cancer will receive an oral dose of iodine-124 and undergo up to four PET scans over several days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Iodine-124
What this could lead to: If successful, this imaging test could help doctors decide whether radioactive iodine therapy will work for each patient, avoiding ineffective treatments.
What could go wrong: This is an early-phase study with only 60 participants, so results may not apply to everyone. The test is for diagnosis only and does not directly treat cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC THYROID CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thyroid cancer thyroid gland carcinoma Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC THYROID CARCINOMA THYROID CARCINOMA

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.